Dr. Paul Wheatley-Price, MD
Claim this profileThe Ottawa Hospital PHASE 2
Studies Tumors
Studies Lung Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
ALK positive
2Lung Cancer
Stage IV
EGFR negative
EGFR positive
Affiliated Hospitals
Clinical Trials Paul Wheatley-Price, MD is currently running
Novel Drug Regimens
for Lung Cancer
This trial is testing new treatment plans that include a drug called belrestotug. It targets patients with advanced lung cancer that has come back or hasn't responded to other treatments. The goal is to see if these new plans work better than the usual treatments.
Recruiting1 award Phase 213 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Paul Wheatley-Price, MD
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Paul Wheatley-Price, MD has experience with
- Repotrectinib (TPX-0005)
- Osimertinib
- Platinum + Pemetrexed
- Cobolimab
- Feladilimab
- Dostarlimab
Breakdown of trials Paul Wheatley-Price, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Metastatic Tumor
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Wheatley-Price, MD specialize in?
Paul Wheatley-Price, MD focuses on Tumors and Lung Cancer. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Paul Wheatley-Price, MD currently recruiting for clinical trials?
Yes, Paul Wheatley-Price, MD is currently recruiting for 3 clinical trials in Ottawa Ontario. If you're interested in participating, you should apply.
Are there any treatments that Paul Wheatley-Price, MD has studied deeply?
Yes, Paul Wheatley-Price, MD has studied treatments such as Repotrectinib (TPX-0005), Osimertinib, Platinum + Pemetrexed.
What is the best way to schedule an appointment with Paul Wheatley-Price, MD?
Apply for one of the trials that Paul Wheatley-Price, MD is conducting.
What is the office address of Paul Wheatley-Price, MD?
The office of Paul Wheatley-Price, MD is located at: The Ottawa Hospital PHASE 2, Ottawa, Ontario K1H 8L6 Canada. This is the address for their practice at the The Ottawa Hospital PHASE 2.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.